Skip to main content

Advertisement

SpringerLink
Log in

Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment

  • Original Paper
  • Published:
Journal of Immigrant and Minority Health Aims and scope Submit manuscript

Abstract

Aims of the study are to investigate, in a cohort of patients affected by HCV chronic hepatitis with genotypes 1 and 4, the prevalence of interleukin 28B (IL28B) genotypes, the possible association between IL28B polymorphism and severity of liver damage, the role of IL28B CC as a predictor of outcome. 365 patients with HCV infection were observed between 2013 and 2014. Demographic, virological, biochemical, and genetic characteristics of each patient were investigated. Liver fibrosis was assessed by transient elastometry. Mean age of the patients (72.9 % males, 27.1 % females) is 50 years. 91.5 % % of patients are Caucasian, 8.5 % African. In the patients with HCV1 and HCV4 a higher frequency of IL28B CT is observed with a prevalence of 52.1 and 61.8 % respectively. As regards ethnic group, African people have a prevalence of 35.5 % for CC, while Caucasians have a prevalence of 23.8 % for CC. In our cohort, IL28B polymorphism does not show significant differences among ethnic groups and in HCV1 and HCV4 genotypes. As described in literature, IL28B CC genotype is confirmed as predictor of sustained virological response in both Caucasians and Africans. A significant correlation between liver fibrosis and IL28B polymorphism emerges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl. 1):74–81.

    Article  PubMed  Google Scholar 

  2. Thompson AJ, Muir A, Sulkowski M, Ge D, Fellay J, Shianna KV, Urban T, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120–9.

    Article  CAS  PubMed  Google Scholar 

  3. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, Mc Hutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.

    Article  CAS  PubMed  Google Scholar 

  5. Suppiah V, Maldovam M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL 28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.

    Article  CAS  PubMed  Google Scholar 

  6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakmoto N, Nakagawa M, Korenaga M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.

    Article  CAS  PubMed  Google Scholar 

  7. Asselah T, De Muynck S, Broet P, Masliah-Planchon J, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56:527–32.

    Article  CAS  PubMed  Google Scholar 

  8. Mangia A, Mottola L, Santoro R. Interleukin 28B plymorphisms as predictor of response in hepatitis C genotype 2 and 3 infected patients. World J Gastroenterol. 2013;19(47):8924–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342–55.

    Article  CAS  PubMed  Google Scholar 

  10. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011;31:45–52.

    Article  PubMed  Google Scholar 

  11. Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772–80.

    Article  CAS  PubMed  Google Scholar 

  12. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, Mc Hutchison JG. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–7.

    Article  CAS  PubMed  Google Scholar 

  13. Mc Carthy JJ, Li JH, Thompson A, Suchindran S, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.

    Article  Google Scholar 

  14. Eslam M, Leung R, Romero-Gomez M et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

  15. Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A. Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Liver Int. 2015;35(2):482–8. doi:10.1111/liv.12630.

    Article  CAS  PubMed  Google Scholar 

  16. Abe H, Ochi H, Maekawa T, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.

    Article  CAS  PubMed  Google Scholar 

  17. Barreiro P, Pineda JA, Rallon N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis. 2011;203:1629–36.

    Article  CAS  PubMed  Google Scholar 

  18. Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384–94.

    Article  CAS  PubMed  Google Scholar 

  19. Ydreborg M, Westin J, Rembeck K, Lindh M, Norrgren H, Holmberg A, Wejstål R, Norkrans G, Cardell K, Weiland O, Lagging M. Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One. 2013;8(11):e80172. doi:10.1371/journal.pone.0080172.eCollection.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fabris C, Falleti E, Cussigh A, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.

    Article  CAS  PubMed  Google Scholar 

  21. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, Soffredini R, Abrignani S, De Francesco R, Colombo M. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54(4):1127–34. doi:10.1002/hep.24503 Epub 2011 Aug 19.

    Article  CAS  PubMed  Google Scholar 

  22. Noureddin M, Wright EC, Alter H, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology. 2013;58:1548–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76:327–32.

    Article  CAS  PubMed  Google Scholar 

  24. Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G, Surace L, De Maria V, Giancotti F, Leone R, Villella V, Nisticò S, Borelli A, Caruso V, Calderazzo M, Griffo G, Masciari R, Minchella P, Cosco L, Laganà C, Oliva A, Foti G, Fiorillo M, Bocchiaro G, Surace P, Ciccaglione A, Ciccozzi M, Cesario F, Torti C, Focà A. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14(Suppl 5):S2. doi:10.1186/1471-2334-14-S5-S2.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Derbala M, Rizk N, Shebl F, Alkaabi S, Eldweik N, John A, Sharma M, Yaqoob R, Almohanadi M, Butt M, Alejji K. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J Gastroenterol. 2012;18(47):7003–8. doi:10.3748/wjg.v18.i47.7003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S. EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–46. doi:10.1016/j.jhep.2014.07.022.

    Article  CAS  PubMed  Google Scholar 

  27. Tamaki N, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, et al. Genetic polymorphism of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS One. 2015;10(9):e0137351. doi:10.1371/journal.pone.0137351.

    Article  PubMed  PubMed Central  Google Scholar 

  28. European Medicines Agency (EMA). Sovaldi registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human med 001723.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 2015.

  29. U.S. Food and Drug Administration (FDA). Sovaldi registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails. Accessed 12 Feb 2015.

  30. European Medicines Agency (EMA). Harvoni registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003850/human med 001813.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 15.

  31. U.S. Food and Drug Administration (FDA). Harvoni registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

  32. European Medicines Agency (EMA). Daklinza registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003768/human med 001792.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 15.

  33. European Medicines Agency (EMA). Olysio registration details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002777/human med 001766.jsp&mid = WC0b01ac058001d124. Accessed 06 Feb 2015.

  34. U.S. Food and Drug Administration (FDA). Olysio registrationdetails. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

  35. U.S. Food and Drug Administration (FDA). Viekirax® + Exviera registra-tion details. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

  36. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918–29. doi:10.1002/hep.26641.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. doi:10.1056/NEJMoa1214853.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute for Health, Migration and Poverty (NIHMP), Via San Gallicano 25/a, 00153, Rome, Italy

    L. Nosotti, A. Petrelli, A. Rossi, G. Costanzo, A. Fortino, L. Miglioresi & C. Mirisola

  2. National Institute for Health (NIH), Rome, Italy

    D. Genovese, S. Catone, C. Argentini & S. Vella

  3. Center for the Study of Liver Diseases, University of Cagliari, Cagliari, Italy

    L. Chessa

Authors
  1. L. Nosotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Petrelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Genovese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Catone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Argentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Vella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Costanzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Fortino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. Chessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L. Miglioresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Mirisola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Nosotti.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nosotti, L., Petrelli, A., Genovese, D. et al. Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. J Immigrant Minority Health 19, 876–882 (2017). https://doi.org/10.1007/s10903-016-0444-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10903-016-0444-9

Keywords

Search

Navigation